tirzepatide cvot results and cardiometabolic parameters in obesity: Summary of current evidence - Sattar - 2025 - Diabetes, Obesity and Metabolism Inside SURPASS-CVOT With Dr. Stephen

If necessary, you can change your injection day as long as the last dose was administered at least three days (72 hours) prior

These factors have particularly impacted individuals with lower health literacy, food/nutrition literacy, and socioeconomic statusperpetuating health inequities for dietrelated diseases [256, 259]

Accessed February 2026.

Nicholls SJ, Bhatt DL, Buse JB et al (2024) Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics

Let it dry

What Tirzepatide is studied for Tirzepatide is a dual GIP/GLP-1 receptor agonist studied for glucose regulation, appetite signalling and metabolic research